Unknown Manufacturer
DG031, deCODE genetics's lead compound, is being developed for the prevention of myocardial infarction, or heart attack.
DG031, deCODE genetics's lead compound, is being developed for the prevention of myocardial infarction, or heart attack.
DG031 inhibits the activity of the FLAP, or 5-lipoxygenase activating protein, that modulates the activity of the leukotriene pathway.
Investigated for use/treatment in heart disease and myocardial infarction.
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
